Scott J Mendelson1, Shuaiqi Zhang1, Roland Matsouaka1, Ying Xian1, Shreyansh Shah1, Barbara L Lytle1, Nicole Solomon1, Lee H Schwamm1, Eric E Smith1, Jeffrey L Saver1, Gregg Fonarow1, Jane Holl1, Shyam Prabhakaran1. 1. From the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.
Abstract
BACKGROUND AND OBJECTIVES: Prior regional or single-center studies have noted that 4% to 7% of eligible patients with acute ischemic stroke (AIS) decline IV tissue plasminogen activator (tPA). We sought to determine the prevalence of tPA declination in a nationwide registry of patients with AIS and to investigate differences in declination by race/ethnicity. METHODS: We used the Get With The Guidelines-Stroke registry to identify patients with AIS eligible for tPA and admitted to participating hospitals between January 1, 2016, and March 28, 2019. We compared patient demographics and admitting hospital characteristics between tPA-eligible patients who received and those who declined tPA. Using multivariable logistic regression, we determined patient and hospital factors associated with tPA declination. RESULTS: Among 177,115 tPA-eligible patients with AIS at 1,976 sites, 6,545 patients (3.7%) had tPA declination as the sole documented reason for not receiving tPA. Patients declining treatment were slightly older, were more likely to be female, arrived more often at off-hours and earlier after symptom onset, and were more likely to present to Primary Stroke Centers. Compared with non-Hispanic White, non-Hispanic Black race/ethnicity was independently associated with increased (adjusted odds ratio [aOR] 1.21, 95% CI 1.11-1.31), Asian race/ethnicity with decreased (aOR 0.72, 95% CI 0.58-0.88), and Hispanic ethnicity (any race) with similar odds of tPA declination (OR 0.98, 95% CI 0.86-1.13) in multivariable analysis. DISCUSSION: Although the overall prevalence of tPA declination is low, eligible non-Hispanic Black patients are more likely and Asian patients less likely to decline tPA than non-Hispanic White patients. Reducing rates of tPA declinations among non-Hispanic Black patients may be an opportunity to address disparities in stroke care.
BACKGROUND AND OBJECTIVES: Prior regional or single-center studies have noted that 4% to 7% of eligible patients with acute ischemic stroke (AIS) decline IV tissue plasminogen activator (tPA). We sought to determine the prevalence of tPA declination in a nationwide registry of patients with AIS and to investigate differences in declination by race/ethnicity. METHODS: We used the Get With The Guidelines-Stroke registry to identify patients with AIS eligible for tPA and admitted to participating hospitals between January 1, 2016, and March 28, 2019. We compared patient demographics and admitting hospital characteristics between tPA-eligible patients who received and those who declined tPA. Using multivariable logistic regression, we determined patient and hospital factors associated with tPA declination. RESULTS: Among 177,115 tPA-eligible patients with AIS at 1,976 sites, 6,545 patients (3.7%) had tPA declination as the sole documented reason for not receiving tPA. Patients declining treatment were slightly older, were more likely to be female, arrived more often at off-hours and earlier after symptom onset, and were more likely to present to Primary Stroke Centers. Compared with non-Hispanic White, non-Hispanic Black race/ethnicity was independently associated with increased (adjusted odds ratio [aOR] 1.21, 95% CI 1.11-1.31), Asian race/ethnicity with decreased (aOR 0.72, 95% CI 0.58-0.88), and Hispanic ethnicity (any race) with similar odds of tPA declination (OR 0.98, 95% CI 0.86-1.13) in multivariable analysis. DISCUSSION: Although the overall prevalence of tPA declination is low, eligible non-Hispanic Black patients are more likely and Asian patients less likely to decline tPA than non-Hispanic White patients. Reducing rates of tPA declinations among non-Hispanic Black patients may be an opportunity to address disparities in stroke care.
Authors: Moira K Kapral; Jennifer Devon; Anne-Luise Winter; Julie Wang; Anne Peters; Susan J Bondy Journal: Med Care Date: 2006-01 Impact factor: 2.983
Authors: Amie W Hsia; Dorothy F Edwards; Lewis B Morgenstern; Jeffrey J Wing; Nina C Brown; Regina Coles; Sarah Loftin; Andrea Wein; Sara S Koslosky; Sabiha Fatima; Brisa N Sánchez; Ali Fokar; M Chris Gibbons; Nawar Shara; Annapurni Jayam-Trouth; Chelsea S Kidwell Journal: Stroke Date: 2011-06-30 Impact factor: 7.914
Authors: Gregg C Fonarow; Xin Zhao; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Deepak L Bhatt; Ying Xian; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: Salvador Cruz-Flores; Alejandro Rabinstein; Jose Biller; Mitchell S V Elkind; Patrick Griffith; Philip B Gorelick; George Howard; Enrique C Leira; Lewis B Morgenstern; Bruce Ovbiagele; Eric Peterson; Wayne Rosamond; Brian Trimble; Amy L Valderrama Journal: Stroke Date: 2011-05-26 Impact factor: 7.914
Authors: Scott J Mendelson; Neelum T Aggarwal; Christopher Richards; Kathleen O'Neill; Jane L Holl; Shyam Prabhakaran Journal: Neurology Date: 2018-01-03 Impact factor: 9.910
Authors: Keith Churchwell; Mitchell S V Elkind; Regina M Benjamin; April P Carson; Edward K Chang; Willie Lawrence; Andrew Mills; Tanya M Odom; Carlos J Rodriguez; Fatima Rodriguez; Eduardo Sanchez; Anjail Z Sharrief; Mario Sims; Olajide Williams Journal: Circulation Date: 2020-11-10 Impact factor: 29.690
Authors: Hugo J Aparicio; Brendan G Carr; Scott E Kasner; Michael J Kallan; Karen C Albright; Dawn O Kleindorfer; Michael T Mullen Journal: J Am Heart Assoc Date: 2015-10-14 Impact factor: 5.501